Premium
Treatment of tinea capitis – griseofulvin versus fluconazole – a comparative study
Author(s) -
Shemer Avner,
Plotnik Ira Bernstein,
Davidovici Batya,
Grunwald Marcelo H.,
Magun Ronen,
Amichai Boaz
Publication year - 2013
Publication title -
jddg: journal der deutschen dermatologischen gesellschaft
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.463
H-Index - 60
eISSN - 1610-0387
pISSN - 1610-0379
DOI - 10.1111/ddg.12095
Subject(s) - griseofulvin , tinea capitis , fluconazole , dermatology , medicine , antifungal
Summary Objective To compare the efficacy and safety of fluconazole and griseofulvin in the treatment of tinea capitis. Patients and Methods Patients with tinea capitis (n = 113) with positive fungal cultures entered the study. The patients were divided into four groups with different treatment regimes. Two groups received griseofulvin 15 or 25 mg/kg/day and two groups received fluconazole 4 or 6 mg/kg/day, all for up to 12 weeks. Results Griseofulvin was found to be slightly better than fluconazole. The lower doses for both griseofulvin and fluconazole required significantly longer treatment duration until mycological cure than the higher doses, independent of the fungus type. Conclusions Since no significant difference was found between the drugs, it is suggested that the choice should be based on tolerability, availability and cost of the drugs.